Brief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
29/10/2026 20:35
BRIEF-Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer Oct 29 (Reuters) - Enanta Pharmaceuticals Inc ENTA.O:
ENANTA PHARMACEUTICALS INC: IN PATENT INFRINGEMENT ACTION AGAINST PFIZER RELATED TO INFRINGEMENT, UPC RULES '265 PATENT INVALID - SEC FILING
ENANTA PHARMACEUTICALS - UPC DETERMINES INFRINGEMENT ACTION AGAINST PFIZER UNFOUNDED - SEC FILING
Further company coverage: ENTA.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma